All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs.

Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Premium Sponsors

Premium Sponsors

Standing Site

MENARIM Standing Company

Johnson & Johnson Innovative Medicine



**Standard Sponsors** 

Takeda

**AMGEN** 

Dr Paola Neri

University of Calgary

**Adaptive** 

Bristol Myers Squibb\*

## **UK Myeloma Society Autumn Day**

## Integration of Immunotherapies in Myeloma Care and Amyloid Update

### Thursday 6<sup>th</sup> November 2025

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

Joint Chairs: Dr Charlotte Pawlyn (Institute of Cancer Research)

Professor Karthik Ramasamy (Churchill Hospital, Oxford)

	<b>Professor Kartnik Ramasamy</b> (Churchill Hospital, Oxford)				
09.00	Registration, coffee & exhibition				
09.25	Welcome and introduction				
09.30	UK practice/access updates	Professor Karthik Ramasamy Churchill Hospital, Oxford			
09.50	College of Myeloma UK - reflections on careers in myeloma	<b>Dr Roger Owen</b> <i>Leeds Teaching Hospitals</i>			
		Professor Mark Drayson University of Birmingham			
	EHA Abstract Award Winners				
10.10	Challenging the concept of functional high-risk myeloma through advanced transcriptional and genetic profiling	<b>Dr Sina Beer</b> <i>Institute of Cancer Research</i>			
	Age-associated marcophage polarization to an M2 phenotype drives myeloma proliferation in the aged bone marrow by loss of tumor-associated phagocytosis	<b>Dr Dominic Fowler-Shorten</b> <i>University of East Anglia</i>			
10:25	Coffee & exhibition				
10.55	IMS Abstract Award Winners				
	The perceptions of frailty and how frailty is assessed in patients living with myeloma – a qualitative exploration of patient perspectives	Jenna Tate Leeds Teaching Hospitals			
	Monitoring and management of CMV and other viral reactivations with bispecific antibodies (BsAbs) for patients with relapsed and refractory multiple myeloma (RRMM)	<b>Dr Alice Feast</b> <i>University College London Hospitals</i>			
	Investigating the role of the BAFF-APRIL system in promoting progression of smouldering myeloma (SMM)	<b>Dr Amatta Mirandari</b> <i>University College London</i>			
	Anti-adhesion properties of KTX-1001, a selective NSD2/MMSET inhibitor, enhance carfilzomib sensitivity in multiple myeloma	<b>Dr Devi Nandana</b> <i>University of Oxford</i>			

13.20 AGM

11.30

12.20

**Michael Morley Lecture** 

Lunch, networking & exhibition

Opportunities and challenges with immunotherapy in myeloma

#### **Parallel Sessions: Clinical and Scientific**

	UKMRA Science Forum	PORTLAND ROOM
	In person attendance only. See next page for more information.	
13.40	Speakers	
15.10	Coffee break	
15.45	Networking and collaboration session	
16.30	Summary and close	
	If you wish to attend this session, please ensure that you select the appropriate pa	ckage when completing your registration.
	Places are limited.	

Clinical Soccion 4: Or	ntimicing the Safe Delivery	of Immunotheranies in the NHS.	<ul> <li>Practical Implementation Updates</li> </ul>

13.40	Prevention and management of side effects with CAR-T/bispecifics	<b>Dr Hannah Hunter</b> <i>University Hospitals Plymouth</i>
13.55	Outpatient bispecific/CAR T delivery experience	<b>Dr Frances Seymour</b> <i>Leeds Teaching Hospitals</i>
14.10	DGH bispecific delivery experience	<b>Dr John Jones</b> <i>University of Sussex</i>
14.25	Safe delivery of ADCs	<b>Dr Kevin Boyd</b> <i>The Royal Marsden</i>
14.40	Panel discussion with case studies	
14.55	Coffee break	
	Clinical Session 2: AL Amyloidosis Update	
15.25	Updates in overall AL amyloid management for 2025	<b>Dr Sriram Ravichandran</b> <i>National Amyloidosis Centre</i>
15.40	Focus on – cardiac amyloidosis	<b>Dr Charlotte Manisty</b> <i>Barts Health NHS Trust</i>
15.55	Focus on – renal amyloidosis and MGRS	<b>Dr Jenny Pinney</b> <i>University Hospitals Birmingham</i>
16.10	Interactive discussion: Structure and function of the new Amyloid network	<b>Professor Ashu Wechalekar</b> <i>National Amyloidosis Centre</i>
_		Professor Guy Pratt University of Birmingham

#### **Registration:**

Standard Fee (until 22 October) £75 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 23 October) £125 (£85 for Scientists, Nurses & Pharmacists)

#### Registration now open at www.collaborativeconferences.co.uk/ukmsociety

Online registration for this meeting is for healthcare professionals only Please indicate if you wish to attend in person or watch the live stream while completing the registration form

Enquiries: Please contact Alex - alex@collaborativeconferences.co.uk

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

### **Premium Sponsors**







Johnson&Johnson Innovative Medicine





sanofi

**Standard Sponsors** 



Close

16.40











All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.



# **UKMRA Science Forum at the UK Myeloma Society Autumn Day**

## Thursday 6<sup>th</sup> November 2025

**Cavendish Conference Centre - PORTLAND ROOM** 

#### **Leading the Session:**

**Dr Shelly Lawson** (Sheffield) and **Dr Sarah Gooding** (Oxford)

13.40	Identifying tumour specific T cell clones in smouldering myeloma	Annabel Laider University College London
13.55	In vivo CRISPR activation screens for developing CAR T cells with superior persistence	Jongwon Yoon University College London
14.10	Origins of mitotic lethality in high-CIN multiple myeloma	<b>Alex Fower</b> <i>University of Oxford</i>
14.25	Prevention, not cure: Investigating MGUS and the challenges of finding a needle in the peripheral blood haystack	<b>Dr Hannah Mackay</b> <i>University of Birmingham</i>
14.40	How do exosomes contribute to treatment failure, with the aim of uncovering key molecular mechanisms driving drug resistance in multiple myeloma	<b>Chloe Wylie</b> <i>Queen's University Belfast</i>
14.55	The role of compass methyltransferase in multiple myeloma	<b>Dr Pierangela Sabbattini</b> Imperial College London
15.10	Coffee break	
15.45	Networking / collaboration session (speed networking)	
16.30	Summary and close	

**Premium Sponsors** 
















**Standard Sponsors** 













All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.